profit from every $100 of sales.
$0$100
BioCardia
$0.83-10.38% today
-36.5% in 1 year
1-year low $0.771-year high $1.47
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BioCardia sold, what it kept, and what it did with the cash.
Sales went from $1.35 million in 2022 to $0 in 2025, with -$8.23 million of profit last year.
SalesProfit
BioCardia vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BioCardia | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads BioCardia's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 0 | 0 | 0 | |
| – | – | – | – | |
| -12 | -12 | -8 | -8 | |
| -12 | -12 | -8 | -8 | |
| -12 | -12 | -8 | -8 | |
| -10.05 | -8.19 | -2.90 | -1.23 | |
| – | – | – | – | |
| -880.3% | -2,441.1% | -13,794.8% | – | |
| -880.7% | -2,425.8% | -13,700.0% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 10 | 3 | 4 | 3 |
| Cash | 7 | 1 | 2 | 2 |
| Total debt | 2 | 1 | 1 | 1 |
| Total liabilities | 5 | 5 | 3 | 3 |
| 5 | -2 | 1 | 1 | |
| 1 | 1 | 3 | 7 | |
| -144.1% | – | -353.5% | -459.6% | |
| -243.4% | 721.8% | -949.3% | -919.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11 | -10 | -8 | -7 | |
| 0 | 0 | 0 | 0 | |
| -11 | -10 | -8 | -7 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 13.3×
- 215.6×
- –
- –
- -63.1%
- -63.5%
- 0.0%
Profitability
- 0.0%
- -13,794.8%
- -13,700.0%
- 0.0%
- -581.7%
- 541.9%
- -28,372.4%
- -241.1%
- -843.8%
- –
Growth
- −79.3%
- –
- +7.3%
- –
- +55.9%
Financial health
- -0.2×
- 0.59
- 15.5%
- –
- 1.12
- 1.12
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 870
Bottom 1%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.21 | -0.17 | −23.5% |
| Mar 24, 2026 | -0.06 | -0.20 | +70.0% |
| Nov 12, 2025 | -0.24 | -0.25 | +4.0% |
| Aug 11, 2025 | -0.40 | -0.25 | −60.0% |
| May 14, 2025 | -0.59 | -0.39 | −51.3% |
| Mar 26, 2025 | -0.25 | -0.87 | +71.3% |
| Nov 13, 2024 | -0.61 | -1.19 | +48.7% |
| Aug 13, 2024 | -0.88 | -0.10 | −780.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
23No pass
Philip Fisher
36No pass
Peter Lynch
22No pass
Joel Greenblatt
2No pass
Charlie Munger
40No pass
Terry Smith
41No pass
Questions about BioCardia
Is BioCardia a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioCardia AI analysis
What does BioCardia do?
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. It is in Biotechnology.
Does BioCardia pay a dividend?
No. BioCardia does not pay a dividend at the moment.
Is BioCardia stock halal?
Yes. BioCardia passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
How has BioCardia stock done over the past year?
Down 36.5% over the past twelve months, to $0.83. It traded between $0.77 and $1.47 and is 43.8% below its high.
Who are BioCardia's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BioCardia's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.